The current study aims to characterize exposure and risk associated to bisphenol-A (BPA) exposure in Slovenia, starting from biomonitoring data. Based on the urinary data, daily intake for the individuals was back-calculated using a physiology based biokinetic (PBBK) model properly parameterized for BPA, coupled with an exposure reconstruction algorithm. Re-running the PBBK model in forward mode allowed the estimation of biologically effective dose (free plasma BPA) and the respective daily area under the curve (AUC). Finally, risk characterization ratio was derived using both external and internal dose metrics. The urinary BPA levels were found low, with GM of 0.79, 1.51 and 0.20 μg/g creatinine for mothers, children and fathers respectively, similar to the levels of other European countries. Based on the above and accounting for the dynamics of exposure and biokinetics, daily intake was estimated, median exposure levels have been estimated equal to 0.019, 0.035 and 0.005 μg/kg_bw/d for mothers, fathers and children respectively. The highest estimated intake level was found in a child, equal to 0.87 μg/kg_bw/d, while the maximum intake for mothers and fathers were 0.7 and 0.8 μg/ kg_bw/d respectively. The respective RCR levels using the EFSA t-TDI of 4 μg/kg_bw/d were 2 magnitudes of order lower below 1, independently of the selected method. It has to be noted that had daily intake been estimated solely based on the urinary concentrations mass balance, the estimated intake would be lower, as a result of the oversimplification on exposure and elimination time dynamics. This highlights the importance for using PBBK modelling based exposure reconstruction schemes for rapidly metabolized and excreted compounds such as BPA, as well as the study design of efficient sampling for rapidly metabolized compounds.
Introduction
Bisphenol A (BPA) is used in the manufacture of polycarbonate plastics and epoxy resins, which are used in baby bottles, as inner protective coatings on food containers, and as composites and sealants in dentistry; BPA may also be used in the thermal paper and polyvinyl chloride industries (Morck, 2012) . BPA is defined as an endocrine disrupting chemical (EDC) that interacts with and elicits responses through endogenous receptors (Aschberger et al., 2010; Oppeneer and Robien, 2015; Rochester, 2013) . Normal functioning of endogenous hormonal systems is essential to the development and growth of the foetus and the reproductive organs in particular. It has been suggested that exposure to BPA may disrupt foetus and young child development. Many in vitro and in vivo (animal) studies demonstrated that adverse health effects due to BPA exposure can occur also at environmentally relevant doses (Rochester, 2013) . It needs also to be highlighted that BPA, together with other EDCs have concurrent exposure with crosstalk and common mechanisms which may lead to dynamic interactions . Several organizations concluded that dietary exposure is the major source of BPA exposure in all age groups of nonoccupationally exposed human subjects (Dekant and Völkel, 2008) . The majority of BPA-leaching consumer products on the market are in direct contact with food, or designed for heating in microwave ovens or for food storage.
Traditionally, risk characterization, includes three steps, namely (a) hazard identification, (b) effects assessment, i.e. the determination of the estimated no-effect level (DNEL) or predicted no-effect level (PNEC) and (c) exposure assessment, i.e. the determination of the predicted environmental concentration (PEC) or human intake or exposure. In many international regulatory frameworks human health risks are often expressed as Intake rate/DNEL and environmental risks as PEC/PNEC ratios, namely risk quotients or risk characterization ratios (RCR). Exposure can be assessed by measuring exposure concentrations, once chemicals are produced, used and emitted. This involves estimating emissions, pathways and rates of movement of a substance and its transformation or degradation in order to obtain concentrations or doses to which human populations or environmental compartments are or may be exposed (bottom up approach). Aiming at having an integrated view of exposure, a large number of human biomonitoring campaigns (on national and international scale) have been initiated, generating a significant amount of human biomonitoring (HBM) data. Although biomonitoring is continuously gaining ground in modern risk assessment, a systematic interpretation of HBM data is still lacking. At the moment, the main pillars for evaluating HBM for risk assessment rely on (a) the comparison of HBM levels to a respective Biomonitoring Equivalent (BE) value and (b) back-calculating intake for direct comparison with the respective reference concentration (RfC) or reference dose (RfD). A BE is defined as the concentration of a chemical or metabolite in a biological medium that is consistent with an existing exposure guidance value criteria including RfDs and RfCs, minimal risk levels (MRLs), or tolerable daily intakes (TDIs) (Hays et al., 2007) . Although BEs provide an interesting screening approach for risk assessment (Hays and Aylward, 2009 ), they do not systematically account for human toxicocinetics, relying on the extrapolation of an animal estimated BE to a human BE, introducing several uncertainty factors. Consequently, translating HBM data into external exposure estimates, is expected to provide a more realistic risk assessment approach. In this context, exposure reconstruction provides a more comprehensive computational framework for HBM data assimilation (Georgopoulos et al., 2008) . Several techniques have been developed in this direction with variable complexity, starting from the exposure conversion factor (ECF) (Tan et al., 2006) , up to combined Maximum Likelihood Estimates coupled to PBBK modelling approaches with synthetic biomarker data under a Bayesian statistics framework (Georgopoulos et al., 2009 ). In practice, back calculation of exposure levels, allows both (a) direct comparison of estimated exposure levels with the relevant external exposure or intake regulatory thresholds; and (b) estimation of internal dose by rerunning forward the internal dosimetry model, accounting for the parameters (age, gender, genetics and route dependent) that induce toxicokinetics variability (Bois et al., 2010) . Efforts for exposure reconstruction regarding BPA have been largely based on intake and excretion equilibrium, relying on BPA rapid metabolism, assuming that the overall amount of BPA is actually excreted in urine (LaKind and Naiman, 2008) . Recently Sarigiannis et al. (2016) showed how to reconstruct exposure to BPA with the use of a toxicokinetic model on EUwide data.
With regard to BPA, a large fraction of the uncertainty in health risk assessment is due to toxicokinetics. BPA toxicokinetics have been extensively studied the latest years, Preliminary efforts to develop PBTK models for BPA were made by Shin et al. (2004) and Teeguarden et al. (2005) , but the most comprehensive model, which clearly illustrated metabolic scaling from adults to neonates-infants was developed by Edginton and Ritter (2009) . Latest studies on BPA toxicokinetics include multiroute and in utero exposure (Martinez et al., 2017; Sarigiannis et al., 2016) , while in a latest study carried out by Sharma et al. (Sharma et al., 2018) , in utero toxicokinetics have been validated using human biomonitoring data. Considering its very rapid metabolism and elimination half-life (t 1/2 ≈ 5 h), accounting only for the ratio between daily intake and the respective reference dose could result in significant exposure misclassification. However, it needs to be highlighted that due to the very rapid metabolism of BPA, first pass metabolism that occurs in liver through orl exposure, is detrimental for its levels in the systemic circulation; it has been estimated that exposure through skin or inhalation might result for internal dose up to six times higher, for the same bodyweight normalized uptake dose (Sarigiannis and Karakitsios, 2011) . On the other hand, translation of BPA exposure dynamics into biologically effective dose (BED) and the use of the respective area under the curve (AUC) provide a more integrative exposure metric with relevance for risk assessment. Based on public and regulatory concerns regarding BPA and the opportunities provided by human biomonitoring, the current study aims at estimating the associated risks to BPA exposure of the Slovenian population (including adult males, females and children) starting from HBM data. Towards this aim, different risk characterization options are investigated that include the use of external intake estimates, BE and AUC, relying on the exposure analysis opportunities provided by the validated PBBK model of .
Material and methods

Overall methodological concept
The current study aims to characterize the risks associated to BPA exposure for the Slovenian population, as well as to highlight the eventual differences in the interpretation of these data when employing different risk characterization options. Towards this aim, the study included the following steps: -Use of the collected and analysed human urine samples from the Slovenian population. -Adjustment of the modelling framework for proper interpretation of the HBM data, namely the PBBK model and the exposure reconstruction algorithm. -Development of the risk characterization framework, where 3 different options were exploited: (a) Comparison of the intake rate derived from HBM data through the exposure reconstruction algorithm with the respective temporary Tolerable Daily Intake (t-TDI) for BPA set by EFSA. (b) Use of the TDI to derive a biomonitoring equivalent (in urine) and comparison of the collected HBM data against it; and (c) Use of the TDI to derive an internal dose equivalent (free BPA in the plasma), and comparison of the respective computed levels of free BPA based on the exposure reconstruction algorithm and HBM data against it. This last method exploits further the exposure analysis opportunities offered by the detailed PBBK model at our avail and allows quantification and exploration of intraspecies variability and uncertainty.
Cohort characteristics
The demographic characteristics of the examined study population are presented in Table 1 . Age of children was evenly distribute between 6 and 11 years, while mothers and fathers age spanned between 30 and 53 years. Based on the BMI of mothers and fathers, and creatinine levels of all participants, the study population was normal; all participants delivered their first morning void and most of them had their last void more than 8 h prior to the sampling. As creatinine levels differed significantly between the study groups, the results were creatinine-adjusted. More details on the population characteristics and the determinants of BPA exposure have been presented by Snoj Tratnik et al. (2019).
Physiology based biokinetic modelling and exposure reconstruction 2.3.1. Physiology based biokinetic modelling
A key component of this study was the use of a comprehensive PBBK model for BPA. For this purpose, the model previously developed by Sarigiannis et al. (2016) has been used. The model describes in detail the absorption, distribution, metabolism, and excretion (ADME) process of both BPA and its conjugated metabolite BPA-Glu, since the main detoxification pathway of BPA is phase II glucuronidation. Scaling to children was explicitly taken into account using the physiologicallybased approach proposed by Edginton et al. (2006) and data about ontogeny of enzymes (glycotransferases) involved in BPA detoxification (Court et al., 2012; Leeder, 2009) . Following a method similar to Edginton and Ritter (2009) , the plasma clearance (CL H ) from adults was converted to an intrinsic clearance (Cl int ) using the well-stirred model and physiologic information of liver blood flow (Q H ; mL/min) and the fraction unbound in plasma (f u ). Elimination through urine (in the form of BPA-Glu) is the only mechanism of elimination. We optimized plasma CLBPA-Glu_kidney during the development of the adult coupled model and compared this with values derived from Volkel et al. (2002) . 
Development of exposure reconstruction modelling framework
Assimilation of human biomonitoring data and their translation into intake distribution amounts to a computational inversion problem, where the objective is to identify the specific input distributions that best explain the observed outputs while minimizing the residual error. Inputs involve spatial and temporal information on micro-environmental media concentrations of xenobiotics and corresponding information on human activities, food intake patterns or consumer product use that result in intakes; outputs are the observed biomonitoring levels.
More in detail, a computational framework was developed based on Bayesian Markov Chain Monte Carlo (MCMC) combined with the generic Physiological Based Pharmacokinetic (PBTK) model aiming at performing accurate exposure reconstruction. Differential Evolution (DE) and MCMC algorithms have been combined to this problem for the first time. The PBTK model has been combined with the Bayesian MCMC (Gilks and Roberts, 1996; Haario et al., 2006) and DEMC (Ter Braak, 2006) techniques in order to simulate and calculate the exposure value that fits best the observed HBM data. The conceptual framework for exposure reconstruction of the process described above is graphically illustrated in Fig. 1 .
In this study, starting from the urinary BPA levels of first morning voids, daily BPA intake was estimated on an individual basis. In practice, the model accounted for:
-the actual urinary volume produced from the latest night void, till the first morning void where the sample was collected -the rate of elimination, based on the creatinine concentration in the morning void and -eventual use of known BPA contamination sources (such as the use of plastic bottle) prior to sampling; in this case, an additional intake dose was assumed beyond the one defined by the typical daily exposure scenario that included 3 meals. Key information regarding their dietary habits (such as consumption of food from PVC containers) and other potential exposure contributors (e.g. occupational exposure) have been retrieved through detailed questionnaires. The summary of the findings is given in Table 2 .
All the above assumptions allowed the more realistic estimation of the predicted (modeled) urinary concentration that had to be converged with the measured one, thus, resulting in a more accurate daily intake.
Risk assessment
Risk characterization of BPA was carried out employing several tools related to external and internal exposure assessment. As a starting point the EFSA t-TDI of 4 μg/kg_bw/d was used (EFSA, 2015) . The options for evaluating exposure levels included: a. Direct comparison of exposure reconstruction intake estimates to EFSA t-TDI of 4 μg/kg_bw/d. b. Use of a biomonitoring equivalent value for urinary data. The reference dose for deriving the BE value was the EFSA t-TDI of 4 μg/ kg_bw/d. It was assumed that this dose is given orally to an adult of 70 kg at a constant rate during the day. This dose was then used as input for the PBBK model. Based on these assumptions, the corresponding BE value was calculated equal to 280 μg/L urinary BPAGlu. c. Since BPA is characterized by rapid clearance, all BPA entering during the day is excreted in urine. Although urine sampling of excreted BPA is representative for the overall daily intake (from all routes), it does not provide any information about internal exposure variability. In order to come up with a more realistic metric for associating intake to internal exposure, free plasma BPA was a Period of time between the last urination and the sample collection. Sarigiannis et al. Environmental Research 170 (2019) 293-300 considered as the most descriptive metric, directly associated to Biologically Effective Dose (BED). This was used in order to capture discrepancies between internal and external exposure due to agedependent differences in the rate of clearance, bioavailability differences based on potential route of exposure and intraday variability of internal dose due to the complexity of exposure scenario. In this case the EFSA t-TDI of 4 μg/kg_bw/d was translated to an area under the curve (AUC) for 24 h, equal to 0.312 μg.24 h/L (for one hour time interval).
Results
External exposure estimates starting from HBM data
Exposure reconstruction was based on the observed biomonitoring data. In order to back calculate exposure, more details at the individual level exposure scenarios had to be accounted for, especially regarding diet, as described in Section 2.3.2. It has also to be noted, that all participants delivered their first morning void and most of them had their last void more than 8 h prior to the sampling. Based on the exposure ancillary information and the HBM data, exposure profiles for the individuals were derived.
Among the population groups included in the study, fathers/ partners had the lowest levels of total BPA (geometric mean (GM) of 0.2 µg/g creatinine), followed by mothers (GM of 0.8 µg/g creatinine) and children (GM of 1.5 µg/g creatinine). Starting from this biomonitoring data and using the exposure reconstruction framework described above, the external exposure (daily uptake) estimates were calculated. The results for the three different groups (mothers, fathers/partners and children) are illustrated in Fig. 2 . Median exposure levels have been estimated equal to 0.019, 0.005 and 0.035 μg/kg_bw/d for mothers, fathers and children respectively. The highest estimated intake level was found in a child, equal to 0.87 μg/kg_bw/d, while the maximum intake for mothers and fathers were 0.7 and 0.8 μg/kg_bw/d respectively.
Internal exposure estimates using the calculated exposure data
Estimation of external exposure, allows the estimation of internal dose (free plasma BPA). Using the calculated uptake levels, internal dose is estimated by running forward the model. This is typically represented by the free plasma BPA. The time course of internal exposure (AUC) and urinary BPA levels under a typical daily exposure scenario for an average child (daily uptake of 0.035 μg/kg_bw/d) are graphically illustrated in Fig. 3 . Internal dose remains low, in the range of ng/L, while the respective AUC (indicated as the shades area under the red line) is in the range of 1.5 ng.24 h/L, which is significantly lower than the one of 0.312 μg.24 h/L, corresponding to a daily intake equal to the t-TDI proposed by EFSA.
Risk characterization
Based on the external and internal exposure estimates described above, as well as on the biomonitoring data itself, RCR were derived for the different age groups. Independently of the RCR method, the median risk for the Slovenian population is low (RCR of about 0.01) (Fig. 4) .
For all 379 individuals, RCR < 1, independently of the employed method. It has to be noted that had RCR been estimated solely based on the urinary concentrations, the estimated risks would be lower. In practice, this is an artifact of the comparison between (a) a steady-state calculated urinary concentration with (b) a urinary concentration that is estimated dynamically in time, accounting for the continuously declining levels of urine eliminated during the night and collected in the first morning void (Fig. 3) . On the other hand, the use of internal dose metrics, did not differentiate significantly the RCR results compared to the external intake results. This is somehow expected, because the former, has been calculated based on intake estimates from individual biomonitoring data, that have already accounted for the individual physiology parameters needed for the PBBK model.
Discussion
Based on the urinary levels of morning void and using the exposure reconstruction framework described above, daily intake was estimated. Median intake levels are in the range of 0.03 μg/kg_bw/d, in accordance with recent studies for BPA daily intake that used bottom up approaches. Daily intake from main dietary sources such as canned food has been estimated at the levels of 0.015 μg/kg_bw/d in Belgium (Geens et al., 2010) , while intake from commonly food items and beverages for Norway was 0.005 μg/kg_bw/d (Sakhi et al., 2014) . Intake estimates for adults by aggregating the contribution from multiple food items was estimated equal to 0.030 μg/kg_bw/d for Europe (von Goetz et al., 2010) , while similar results have also been reported for Canada (0.17-0.08 μg/kg_bw/d) reported by Cao et al. (2011) and USA (0.013 μg/kg_bw/d), reported by Lorber et al. (2015) . Details on the estimated exposure levels for several regions are given in Table 3 .
However, given the uncertainties related to bottom-up approaches, the latest years, there is growing body in literature where BPA daily intake is approximated using urinary BPA levels (Huang et al., 2018) . Considering the very rapid metabolism of BPA, it is assumed that a 24-h urine sample approximates the BPA intake from the previous 24 h ( LaKind and Naiman, 2008) . Based on the above assumption, the median daily BPA intake for the US population was estimated at 0.025 μg/kg_bw/d (LaKind and Naiman, 2015). However, intake estimates based on BPA daily mass balance are representative only when the whole day urine is collected. When this is applied in spot samples, the overall intake might be seriously misinterpreted. Significant changes of BPA urinary levels, subjected to the exposure events . On the contrary, the use of an exposure reconstruction algorithm, allows the correct interpretation of a spot sample, since exposure and elimination time dynamics are properly described (as shown in Fig. 3 ). In addition, the use of a PBBK model in this study, simplifies the needs for creatinine adjustment, since this information is already introduced in the PBBK model parameterization; The results of urinary BPA are creatinine adjusted, accounting for the age and gender dependent differences in daily creatinine excretion; since exposure reconstruction is based on multiple iterations of the PBBK model, these differences are explicitly accounted for. Had we not used a PBBK model, but a mass balance equilibrium, the approach proposed by LaKind and Naiman (2015) should be used, that accounts for the ratio of male to female creatinine-adjusted urinary BPA levels, expressed as a ratio of ratios (unadjusted urinary BPA / creatinine-adjusted urinary BPA).
Another major advantage of exposure reconstruction, is the capability to re-run forward the PBBK model, accounting for all potential parameters that induce bioavailability differences. In a nutshell, these Sarigiannis et al. Environmental Research 170 (2019) 293-300 include age, route of exposure and genetic variability. The effect of age is related to differences in (a) physiological parameters such as tissue composition, blood flows, cardiac and respiratory rate and (b) the maturity of the conjugation activity. Taking into account the physiologically-based approach for scaling to children (Edginton et al., 2006) and the most recent findings regarding the ontogeny of enzymes involved in BPA detoxification (Court et al., 2012 (Court et al., , 2011 Leeder, 2009 ) an age-dependent bioavailability difference factor of 2-3.5 is considered between infants and adults. Similarly, significant bioavailability differences occur based on the route of exposure; In the case of inhalation, BPA enters directly in the blood stream from the alveoli and the lack of first pass metabolism results in bioavailability differences up to 6 times compared to a similar dose administrated orally (Sarigiannis and Karakitsios, 2011) . In the case of dermal exposure, the lack of first pass metabolism is somehow decompensated by slower absorption (Zalko et al., 2011 ). Finally, a major factor that differentiates BED within a population is the presence of genetic variants of key enzymes involved in BPA conjugation; in vitro kinetic studies have identified that D85Y substitution in UGT2B15 decreases enzymatic function (Hanioka et al., 2011) and that the polymorphic alleles of UGT2B15 are translated in variations in the metabolism of BPA (Partosch et al., 2013) . The effect of all the described above parameters is summarized in Fig. 5 , where for the same bodyweight normalized dose, free plasma BPA is estimated accounting for differences in age, route of exposure and genetics. Clearly, the combination of early infancy and the presence of alleles associated to slower metabolism could result in a biologically effective dose in a neonate or an infant up to 15 times higher compared to the one of an adult. This leads to the conclusion, that a phenomenally limited variability in biomonitored data could be realistically translated into a wider BED variability. In the case that additional information had been available (such as genetic polymorphisms) or younger children and infants were enrolled in the study, wider differences would had been identified in the respective RCR outcomes among the different approaches. It has to be noted that, although exposure levels of BPA as the ones estimated in Slovenia are considered safe (using the EFSA (t-TDI) as reference dose), several cohort studies have recently associated environmentally relevant BPA exposure levels with adverse health effects. Exposure to BPA above a certain threshold (4.5 μg/g creatinine in mother urine) during pregnancy has been associated with higher diastolic blood pressure of the children (Bae et al., 2017) , while other studies have associated environmentally relevant exposure levels with autism spectrum disorders (Stein et al., 2015) and obesity (Oppeneer and Robien, 2015) . It is expected that future cohort studies that properly account for differences in BED (and not only for differences in the biomonitored data), would provide more robust associations between BPA exposure levels and potential health effects.
Despite the advantages of using a comprehensive PBBK model coupled with exposure reconstruction algorithms to properly interpret the biomonitoring spot urine samples, additional steps are needed towards a comprehensive understanding of the potential adverse effects of BPA. Firstly, we need to always keep in mind that BPA is one of the most rapidly metabolized industrial compounds; thus, to better identify the potential exposure sources, more than one measurements in urine samples per day are required. These are essential for a more accurate description of the time-dependent profile of internal dose and the respective AUC calculation. Moreover, it would be of particular importance to understand how the different exposure regimes and internal exposure profiles induce early biological responses; metabolomics analysis of the respective urine samples and the subsequent pathway Fig. 5 . Understanding the major parameters inducing bioavailability differences. D.A. Sarigiannis et al. Environmental Research 170 (2019) 293-300 analysis using big data analytics and advanced bioinformatics (Manrai et al., 2016) could shed additional light in the potential homeostasis perturbation in relation to BPA exposure. This is the direction of our future work, where the various daily intake estimates will be further associated with responses of molecular targets. Overall, answering the question whether BPA at current exposure levels eventually results in adverse health outcomes, requires the integration of environmental and molecular epidemiology and toxicology, with detailed exposure related data (e.g. food questionnaires), multiple daily urine samples collection, internal dose analysis, -omics pathway analysis, and evaluation of both in vitro and in vivo data. In this content, the capability offered by the PBBK models to estimate BED is expected to provide more accurate exposure metrics for environment wide association studies, as well as for linking real-life exposure with biologically effective dose in in vitro models (Judson et al., 2011) .
Conclusions
Starting from HBM data collection and using a physiology based biokinetic model coupled with an exposure reconstruction algorithm, exposure to BPA in the Slovenian population was found to be at par with other European countries. The mean daily intake was estimated to be almost 2 orders of magnitude lower than the respective EFSA t-TDI of 4 μg/kg_bw/d. Among the investigated population groups, higher mean intake levels were estimated for children. On the other hand, the similar maximum exposure estimates (close to 0.8 μg/kg_bw/d) for all age groups, indicates that significant exposure sources still occur for both adults and children. On the other hand, these exposure levels might result in a daily AUC similar to the one derived by t-TDI, depending on the presence of alleles associated to slower metabolism of the individuals.
The multi-faceted method presented herein, provides more accurate daily intake estimates compared to the method based on urinary concentrations mass balance, since the use of physiology based biokinetic modelling allows the comprehensive description of exposure and elimination time dynamics. This highlights the importance for using PBBK modelling based exposure reconstruction schemes for rapidly metabolized and excreted compounds such as BPA. In addition, translating biomonitoring data into internal dose estimates and accounting for the parameters that induce interindividual variability, will provide more accurate exposure metrics for future associations towards a better assessment of potential adverse health effects.
